Abbott Laboratories Earnings - Q3 2026 Analysis & Highlights
Abbott reported accelerating third-quarter sales and EPS growth, while announcing a planned Nutrition spin-off; discussion also covered segment performance, product launches, reimbursement and pricing dynamics, and the company’s outlook.
Key financial results
Third-quarter sales increased 7% on a comparable basis, and adjusted EPS was $1.42, up 9% year over year and in line with guidance and consensus.
Adjusted gross margin was 57.2%, up 140 basis points year over year; adjusted operating margin was 23.4%, up 40 basis points.
Adjusted R&D was 6.9% of sales and adjusted SG&A was 26.9% of sales.
Foreign exchange reduced third-quarter sales growth by 0.4% year over year.
Business segment results
Diagnostics sales grew 6.5%; Core Laboratory grew 5.5%, supported by performance in the U.S., Europe, Japan, and Latin America.
Cancer Diagnostics grew 14%, led by Cologuard, with contributions from precision oncology and international business; Cologuard grew at a mid-teens rate.
Nutrition sales increased 5%, with growth across all four pediatric and adult, U.S. and international categories; pediatric nutrition grew 9% and adult nutrition 2%.
Established Pharmaceuticals sales increased 8.5%, with broad-based growth across geographies and therapeutic areas, including double-digit growth in several countries.
Medical Devices sales grew 8%, led by double-digit growth in electrophysiology and rhythm management; electrophysiology growth was in the mid-to-high teens excluding LAA, while rhythm management grew 10%.
Diabetes-care continuous glucose monitoring sales grew 8% in the quarter.
Exact Sciences’ operating margin was in the high teens exiting the quarter, according to management.
Capital allocation
Abbott plans a tax-free distribution of shares in the new Nutrition company to Abbott shareholders; the separation is anticipated by the end of 2027, subject to required approvals.
Abbott expects the new company to raise debt, with a portion of proceeds distributed to Abbott; the amounts have not yet been determined.
Abbott expects both companies’ dividends, combined, to equal Abbott’s dividend at the time of separation.
Management said Abbott intends to grow its dividend next year, expects the final large debt-paydown tranche related to the St. Jude and Alere acquisitions this year, and sees opportunity for share repurchases.
Abbott expects separation-related costs, which it will treat as specified items excluded from adjusted earnings.
Industry trends and dynamics
Management described Nutrition as a market increasingly shaped by consumer preferences, wellness trends, and retail execution, with growing consumer attention to metabolic health and nutrition’s role in wellness and disease prevention.
Abbott said U.S. and global testing demand remained healthy and at durable levels during the quarter.
Management characterized the CGM market as lacking significant recent reimbursement expansion, and said limited reimbursement expansion is affecting access to the non-insulin Type 2 population.
Abbott cited greater international pricing pressure in CGM as competition increases, and said it expects pricing adjustments over the next few quarters.
Management said LAA market dynamics and customers waiting for Abbott’s new device are creating a near-term headwind for electrophysiology growth.
Competitive landscape
Abbott said WIC contract wins helped it regain U.S. market leadership in both WIC and non-WIC pediatric nutrition segments.
Management said Abbott’s Volt PFA catheter was driving adoption and that the company continued to capture share in Europe; it also said Abbott expected to continue taking market share in electrophysiology despite near-term headwinds.
Abbott described its new CRC blood test alongside Cologuard as giving it both blood-based and stool-based screening options; management said stool testing has better performance in detecting precancerous lesions.
Management said Abbott would make CGM pricing adjustments to defend international market share, rather than risk losing share based on price.
Macroeconomic environment
Foreign exchange was an unfavorable factor for third-quarter sales, and Abbott forecast an approximately 1% negative impact on fourth-quarter sales at current rates.
Management described the global operating environment as volatile but did not provide specific commentary on inflation, tariffs, trade, or recession.
Growth opportunities and strategies
Abbott’s rationale for separating Nutrition is to give both businesses greater strategic and operational focus, enabling each to direct resources and improve commercial and R&D effectiveness.
Abbott said the Nutrition company would have approximately $8.5 billion in annual sales, 16,000 employees, and 14 manufacturing sites, and would be a globally scaled pure-play healthy nutrition company.
Management expects Abbott’s post-separation portfolio to have higher growth and margin profiles; excluding Nutrition’s current profile, Abbott estimated sales growth would accelerate by 50–100 basis points, gross margin increase by more than 200 basis points, and operating margin increase by approximately 100 basis points.
Abbott cited product and pipeline opportunities including Volt and TactiFlex Duo in electrophysiology, Libre Duo in diabetes care, a coronary IVL program, and new cancer diagnostic tests.
Abbott said it is increasing R&D investment, with spending expected to exceed $3 billion this year and increase further next year.
Management said the Nutrition spin-off would not constrain M&A; it expects potential deals to be more likely tuck-ins than transformative acquisitions while it focuses on Exact Sciences integration.
Financial Guidance and Outlook
Abbott forecast fourth-quarter adjusted EPS of $1.62–$1.67 and said foreign exchange would negatively affect fourth-quarter sales by approximately 1% at current rates.
Management said the full-year sales-growth outlook of roughly 6% implies slightly more than 8% growth in the fourth quarter.
Abbott attributed the revised fourth-quarter outlook mainly to electrophysiology and diabetes; it expected EP growth of about 20% in Q4 and diabetes growth in the low-to-mid-single digits over the next few quarters.
For 2027, management said it expects total-company growth to accelerate, but would take a more conservative approach to initial sales guidance; it did not provide specific 2027 EPS guidance, saying details would come in January.
Management expects continued gross-margin expansion, earnings growth, investment in product pipelines, strong cash flow, and dividend growth, without providing specific amounts for those outlook items.
